Exagen Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Exagen Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-20.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 58% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$131Sales grew 46% in 3 years; of every extra $100 of sales, $131 became extra profit.
Higher than 84% of Healthcare companies in United States.
Asset Productivity Ratio
+46% / -33%In 3 years sales changed by +46% while total assets changed by -33%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-21.2×Operating cash was negative last year, while some debt falls due within a year.
Lower than 55% of Healthcare companies in United States.
Cash Cushion Ratio
+4%Cash, after subtracting all debt, equals 4% of its market value (net cash).
Lower than 61% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Exagen Inc. made a loss over the last year. Exagen Inc. owes $0.76 for every $1 it owns. Exagen Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossExagen Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
14.83The share price is 14.83 times Exagen Inc.'s book value per share, higher than 90% of Healthcare companies in United States.
Market cap
$181 MThe total market value of all of Exagen Inc.'s shares at today's price (share price × number of shares), smaller than 59% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$12 MWhat Exagen Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.50Net worth divided by the number of shares. The share price of $7.48 is 14.8 times this, which is the P/B above.
Return on equity (ROE)
-113.8%Exagen Inc. lost 113.8% of its shareholders' money over the last year, lower than 74% of Healthcare companies in United States.
Owes vs Owns
0.76×Exagen Inc. owes $0.76 for every $1 it owns (moderate), higher than 76% of Healthcare companies in United States.
Dividend yield
NoneExagen Inc. does not currently pay a dividend.
Revenue growth
+20%Revenue rose 20% in the year to Dec 2025, and grew 13% a year on average over 3 years.
Profit growth
LossExagen Inc. made a loss in each of the last two years.
Profit margin
-30.0%Exagen Inc. lost $30 for every $100 of revenue.
Interest cover
Not coveredExagen Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashExagen Inc. held $7 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Exagen Inc.: $181 M ÷ $12 M (30 Jun 2026) = 14.8.
What is Exagen Inc.'s return on equity?
Exagen Inc. lost 113.8% of its shareholders' money over the last year, lower than 74% of Healthcare companies in United States.
How much does Exagen Inc. owe compared with what it owns?
Exagen Inc. owes $0.76 for every $1 it owns (moderate), higher than 76% of Healthcare companies in United States.
Does Exagen Inc. pay a dividend?
No. Exagen Inc. does not currently pay a dividend.
Is Exagen Inc.'s revenue growing?
Revenue rose 20% in the year to Dec 2025, and grew 13% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.